What Share Rights are reported by the Telix (TLX) CFO?

The CFO holds Share Rights over 1,111 ordinary shares expiring March 31, 2028 and 14,741 ordinary shares expiring March 31, 2029. Each Share Right represents a contingent right to receive one ordinary share, subject to vesting and forfeiture conditions.

When did the Telix (TLX) CFO’s PSARs and Share Rights vest or become exercisable?

Footnotes state PSARs granted in October 2022 became vested and exercisable on March 6, 2025, later PSARs on March 12, 2026, and certain Share Rights granted January 1, 2025 vested March 5, 2026, with additional March 18, 2026 Share Rights vesting around February or March 2027.

Telix CFO reports equity awards and holdings

Q: What Performance Share Appreciation Rights does the Telix (TLX) CFO hold?

He holds PSARs over 45,449 and 32,463 ordinary shares at an exercise price of 6.1500, expiring October 24, 2027, and over 88,497 ordinary shares at an exercise price of 6.9000, expiring December 31, 2027, all reported in Australian Dollars.

Telix Pharmaceuticals Ltd Group Chief Financial Officer Darren Charlton Smith has filed an initial ownership report showing a mix of ordinary shares and equity awards.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd Group Chief Financial Officer Darren Charlton Smith has filed an initial ownership report showing a mix of ordinary shares and equity awards. He holds 10,810 Ordinary Shares directly. He also holds Performance Share Appreciation Rights over 45,449 and 32,463 Ordinary Shares at an exercise price of 6.1500 (Australian Dollars) expiring on October 24, 2027, and over 88,497 Ordinary Shares at an exercise price of 6.9000 expiring on December 31, 2027. In addition, he holds Share Rights over 1,111 Ordinary Shares expiring March 31, 2028 and 14,741 Ordinary Shares expiring March 31, 2029. Footnotes state that the PSARs and certain Share Rights were granted between October 2022 and March 2026 and became, or will become, vested and exercisable based on continued service and testing after the audited calendar year 2026 financial results.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Smith Darren Charlton

Role Group Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Performance Share Appreciation Rights (right to buy)	--	--	--
holding	Performance Share Appreciation Rights (right to buy)	--	--	--
holding	Performance Share Appreciation Rights (right to buy)	--	--	--
holding	Share Rights	--	--	--
holding	Share Rights	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Performance Share Appreciation Rights (right to buy) — 166,409 contracts (Direct); Share Rights — 15,852 contracts (Direct); Ordinary Shares — 10,810 shares (Direct)

Footnotes (6)

F1. The performance share appreciation rights (PSARs) were granted on October 24, 2022, and became vested and exercisable on March 6, 2025.
F2. Conversion price is reported in Australian Dollars.
F3. The PSARs were granted on October 24, 2022 and became vested and exercisable on March 6, 2025.
F4. The PSARs were granted on April 25, 2023 and became vested and exercisable on March 12, 2026.
F5. The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026.
F6. The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share.

Key Figures

Ordinary Shares held: 10,810 shares PSARs at 6.1500 (tranche 1): 45,449 underlying shares PSARs at 6.1500 (tranche 2): 32,463 underlying shares +3 more

6 metrics

Ordinary Shares held 10,810 shares Direct holdings reported on Form 3

PSARs at 6.1500 (tranche 1) 45,449 underlying shares Exercise price 6.1500, expiration October 24, 2027, direct

PSARs at 6.1500 (tranche 2) 32,463 underlying shares Exercise price 6.1500, expiration October 24, 2027, direct

PSARs at 6.9000 88,497 underlying shares Exercise price 6.9000, expiration December 31, 2027, direct

Share Rights 2028 1,111 underlying shares Exercise price 0.0000, expiration March 31, 2028, direct

Share Rights 2029 14,741 underlying shares Exercise price 0.0000, expiration March 31, 2029, direct

Key Terms

Performance Share Appreciation Rights, Share Rights, vested and exercisable, conversion price, +1 more

5 terms

vested and exercisable financial

"became vested and exercisable on March 6, 2025"

conversion price financial

"Conversion price is reported in Australian Dollars."

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

contingent right financial

"Each SR represents the contingent right to receive one ordinary share."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Telix Pharmaceuticals (TLX) CFO Darren Smith report in this Form 3?

Telix Pharmaceuticals CFO Darren Smith reports initial holdings of 10,810 ordinary shares, plus several tranches of Performance Share Appreciation Rights and Share Rights that can convert into ordinary shares if vesting and exercise conditions are met over the coming years.

How many ordinary shares does the Telix (TLX) CFO directly own?

The Telix CFO directly owns 10,810 ordinary shares. In addition to these shares, he holds multiple equity awards in the form of Performance Share Appreciation Rights and Share Rights that relate to additional underlying ordinary shares upon exercise.

Are Telix (TLX) CFO Darren Smith’s equity awards subject to forfeiture conditions?

The Share Rights granted March 18, 2026 are subject to forfeiture if employment is terminated for cause, and vesting depends on continued service and testing after audited calendar year 2026 financial results, according to the disclosed footnote language.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/01/2026 - 07:25 AM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Smith Darren Charlton

(Last)

(First)

(Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE

3051

(City)

(State)

(Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

3a. Foreign Trading Symbol
[TLX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Group Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	10,810	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Performance Share Appreciation Rights (right to buy)	⁽¹⁾	10/24/2027	Ordinary Shares	45,449	$6.15⁽²⁾	D
Performance Share Appreciation Rights (right to buy)	⁽³⁾	10/24/2027	Ordinary Shares	32,463	$6.15⁽²⁾	D
Performance Share Appreciation Rights (right to buy)	⁽⁴⁾	12/31/2027	Ordinary Shares	88,497	$6.9⁽²⁾	D
Share Rights	⁽⁵⁾	03/31/2028	Ordinary Shares	1,111	$0	D
Share Rights	⁽⁶⁾	03/31/2029	Ordinary Shares	14,741	$0	D

Explanation of Responses:

1. The performance share appreciation rights (PSARs) were granted on October 24, 2022, and became vested and exercisable on March 6, 2025.

2. Conversion price is reported in Australian Dollars.

3. The PSARs were granted on October 24, 2022 and became vested and exercisable on March 6, 2025.

4. The PSARs were granted on April 25, 2023 and became vested and exercisable on March 12, 2026.

5. The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026.

6. The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share.

Remarks:

Ex. 24 - Power of Attorney

	/s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR